Neurology · Washington D.C., DC
Neurology studies in Washington D.C., DC
41 recruiting studies have a site in Washington D.C..
41 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersEarly Phase 1
Assistance Delivery and Muscle Coordination
The Catholic University of America
- Location
- Washington D.C., DC
- Eligibility basics
- Ages 20–80
- RecruitingHealthy volunteersEarly Phase 1
Sensory Feedback and Hand Motor Adaptation
The Catholic University of America
- Location
- Washington D.C., DC
- Eligibility basics
- Ages 20–70
- RecruitingPhase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
TG Therapeutics, Inc.
- Location
- Washington D.C., DC + 35 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
argenx
- Location
- Washington D.C., DC + 15 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
argenx
- Location
- Washington D.C., DC + 12 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated
- Location
- Washington D.C., DC + 57 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
Pfizer
- Location
- Washington D.C., DC + 28 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Novartis Pharmaceuticals
- Location
- Washington D.C., DC + 42 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
Dianthus Therapeutics
- Location
- Washington D.C., DC + 29 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
AllRock Bio, Inc.
- Location
- Washington D.C., DC + 10 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
Celgene
- Location
- Washington D.C., DC + 31 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Bristol-Myers Squibb
- Location
- Washington D.C., DC + 23 other US sites
- Eligibility basics
- Ages 60–85
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Hoffmann-La Roche
- Location
- Washington D.C., DC + 52 other US sites
- Eligibility basics
- Ages 50–85
- RecruitingPhase 2
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Immunovant Sciences GmbH
- Location
- Washington D.C., DC + 30 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
UCB Biopharma SRL
- Location
- Washington D.C., DC + 41 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 2
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
ACADIA Pharmaceuticals Inc.
- Location
- Washington D.C., DC + 27 other US sites
- Eligibility basics
- Ages 55–84
- RecruitingPhase 1
A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
Pfizer
- Location
- Washington D.C., DC + 10 other US sites
- Eligibility basics
- Ages 6–11
- RecruitingPhase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Pfizer
- Location
- Washington D.C., DC + 69 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Pfizer
- Location
- Washington D.C., DC + 54 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
Novartis Pharmaceuticals
- Location
- Washington D.C., DC + 39 other US sites
- Eligibility basics
- Ages 21–70
- RecruitingPhase 2/Phase 3
Optimizing Reperfusion to Improve Outcomes and Neurologic Function
Corxel Pharmaceuticals
- Location
- Washington D.C., DC + 19 other US sites
- Eligibility basics
- Ages 18–90
- RecruitingPhase 3
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie
- Location
- Washington D.C., DC + 87 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Novartis Pharmaceuticals
- Location
- Washington D.C., DC + 42 other US sites
- Eligibility basics
- Ages 40–70
- RecruitingPhase 1
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
AstraZeneca
- Location
- Washington D.C., DC + 4 other US sites
- Eligibility basics
- Ages 18–60
Who these studies look for
Most require a confirmed diagnosis; memory studies often ask for a study partner who knows you well to attend some visits.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.